Further sequencing analysis of the tumor sample revealed several molecular alterations, including deletion of α thalassemia/mental retardation syndrome X-linked (ATRX), pathogenic mutations with corresponding loss of heterozygosity in tumor protein 53 (TP53) and Neurofibromatosis 1 (NF1), single copy deletion of breast cancer 2 (BRCA2) and retinoblastoma 1 (RB1), and amplification of cyclin dependent kinase 4 (CDK4). This evidence concerns the gene ATRX and neoplasm.